Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 12, 2021
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort" is focused on studying colorectal and pancreatobiliary cancers, which have become more common in recent years. Researchers want to understand how the environment around tumors and the body's immune system interact and influence the way these cancers grow and respond to treatment. The goal is to find new ways to diagnose and treat these cancers by looking at factors like the tumor's surroundings, the immune system, and even gut bacteria. This could help doctors predict how well a patient might do with certain treatments and what side effects they might experience.
To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of colorectal or pancreatic adenocarcinoma (a type of cancer) or biliary tract adenocarcinoma, diagnosed since 2015. The study aims to include all eligible patients, regardless of their cancer stage or current treatment. Participants can expect to provide consent and have their medical information reviewed, contributing to important research that could lead to better treatment options for digestive cancers in the future. It's important to note that individuals who are pregnant, breastfeeding, or have certain legal or medical restrictions may not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma
- • Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment
- • Age ≥ 18 years old
- • Diagnosed from 2015 onwards
- • Signed Consent
- • Affiliation to a social security scheme (including CMU (Universal health coverage))
- Exclusion Criteria:
- • Patient under guardianship, curatorship or safeguarding of justice
- • Pregnant or breastfeeding woman
- • Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.
- • Refusal to participate in the study
- • Patient on AME (state medical assistance)
- • Persons deprived of liberty by a judicial or administrative decision
- • Persons under psychiatric care
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pr Tournigand
Study Director
AP-HP Henri Mondor Créteil
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials